



1 June 2022

## Tender results

Pharmac has resolved to award tenders for:

- Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021;
- Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020; and
- Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status, Sole Subsidised Supply, or Hospital Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of June 2022 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of

Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

### **CORRECTION to May 2022 Tender Notification**

The May 2022 tender notification notified the incorrect Principal Supply dates for ‘atazanavir sulphate – cap 150 mg’ and ‘atazanavir sulphate – cap 200 mg’.

The May 2022 tender notification also notified the incorrect pack type for ‘atazanavir sulphate – cap 150 mg’

Corrections in **red**, **bold** and strikethrough below.

## **2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023**

### **Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

- Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply Brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Erlotinib hydrochloride	Tab 100 mg; 30 tablet blister pack	\$764.00	\$329.70	Alchemy (Alchemy)	1 September 2022	1 February 2023	Tarceva (Roche)
Erlotinib hydrochloride	Tab 150 mg; 30 tablet blister pack	\$1146.00	\$569.70	Alchemy (Alchemy)	1 September 2022	1 February 2023	Tarceva (Roche)

## Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Erlotinib hydrochloride	Tab 100 mg; 30 tablet blister pack	\$764.00	\$329.70	Alchemy (Alchemy)	1%	1 September 2022	1 February 2023	Tarceva (Roche)
Erlotinib hydrochloride	Tab 150 mg; 30 tablet blister pack	\$1146.00	\$569.70	Alchemy (Alchemy)	1%	1 September 2022	1 February 2023	Tarceva (Roche)

**2020/21 Tender – Principal Supply Status applies until 30 June 2024**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date
Nitrofurantoin	Tab 50 mg; 100 tablet bottle	\$22.20	\$22.20	Nifuran (W M Bamford & Co)	1 July 2022	1 December 2022
Nitrofurantoin	Tab 100 mg; 100 tablet bottle	\$37.50	\$37.50	Nifuran (W M Bamford & Co)	1 July 2022	1 December 2022

**Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule**

4. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Nitrofurantoin	Tab 50 mg; 100 tablet bottle	\$22.20	\$22.20	Nifuran (W M Bamford & Co)	5%	1 July 2022	1 December 2022

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Nitrofurantoin	Tab 100 mg; 100 tablet bottle	\$37.50	\$37.50	Nifuran (W M Bamford & Co)	5%	1 July 2022	1 December 2022

**2021/22 Tender – Principal Supply Status applies until 30 June 2025**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

5. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date
Fludrocortisone acetate	Tab 100 mcg; 100 tablet bottle	\$14.32	\$11.46	Florinef (Aspen)	1 July 2022	1 December 2022
Oxytocin with ergometrine	Inj 5 IU with ergometrine maleate 500 mcg per ml, 1ml; 5 ampoule pack	\$30.00	\$32.40	Syntometrine (Max Health)	1 July 2022	1 December 2022

6. *Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Atazanavir sulphate	Cap 150 mg; 60 capsule blister pack <del>bottle</del>	\$141.68	\$85.00	Atazanavir Mylan (Viatris)	1 December 2022	1 February 2023 <del>February</del> May	Teva (Teva)
Atazanavir sulphate	Cap 200 mg; 60 capsule blister pack	\$188.91	\$110.00	Atazanavir Mylan (Viatris)	1 December 2022	1 February 2023 <del>February</del> May	Teva (Teva)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Bisacodyl <sup>1</sup>	Tab 5 mg; 200 tablet blister pack	\$5.80	\$5.80	Bisacodyl Viatris (Viatris)	1 August 2022	1 January 2023	Pharmacy Health (API Consumer Brands)
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule; 10 ampoule pack	\$33.50	\$24.48	Wockhardt (Max Health)	1 November 2022	1 April 2023	Nozinan (Sanofi)
Liquid paraffin with white soft paraffin	Oint liquid paraffin 50% with white soft paraffin 50%; 500 g tub OP	\$5.35	\$4.94	White Soft Liquid Paraffin AFT (AFT)	1 December 2022	1 May 2023	healthE (Jaychem)
Paracetamol	Oral liq 120 mg per 5 ml; 200 ml bottle	\$5.45 (per 1,000 ml)	\$3.98	Paracetamol (Ethics) (Multichem NZ)	1 January 2023	1 June 2023	Paracare (API Consumer Brands)
Paracetamol	Oral liq 250 mg per 5 ml; 200 ml bottle	\$6.25 (per 1,000 ml)	\$3.35	Pamol (Aspen Pharma)	1 November 2022	1 April 2023	Paracare Double Strength (API Consumer Brands)
Sodium cromoglicate	Eye drops 2%; 10 ml dropper bottle OP	\$1.79 (per 5 ml)	\$2.62	Allerfix (Teva)	1 October 2022	1 March 2023	Rexacrom (Rex Medical)
Thiamine hydrochloride	Tab 50 mg; 100 tablet bottle	\$7.09	\$4.65	Thiamine multichem (Multichem)	1 November 2022	1 April 2023	Max Health (Max Health)
<sup>1</sup> Stock is expected to become available within August, a 1 August 2022 Pharmaceutical Schedule listing date has been applied to enable subsidised dispensing of this product within August.							

See table 8 below for changes to section B of the Pharmaceutical Schedule in relation to bortezomib.

## Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

### 7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of listing	Principal Supply Status date
Fludrocortisone acetate	Tab 100 mcg; 100 tablet bottle	\$14.32	\$11.46	Florinef (Aspen)	5%	1 July 2022	1 Decemeber 2022
Oxytocin with egometrine	Inj 5 IU with ergometrine maleate 500 mcg per ml, 1ml; 5 ampoule pack	\$30.00	\$32.40	Syntometrine (Max Health)	5%	1 July 2022	1 December 2022

8. *Tenders awarded to Pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Atazanavir sulphate	Cap 150 mg; 60 capsule <del>blister pack</del> bottle	\$141.68	\$85.00	Atazanavir Mylan (Viatris)	5%	1 December 2022	1 February <del>February</del> May 2023	Teva (Teva)
Atazanavir sulphate	Cap 200 mg; 60 capsule blister pack	\$188.91	\$110.00	Atazanavir Mylan (Viatris)	5%	1 December 2022	1 February <del>February</del> May 2023	Teva (Teva)
Bisacodyl <sup>2</sup>	Tab 5 mg; 200 tablet blister pack	\$5.80	\$5.80	Bisacodyl Viatris (Viatris)	5%	1 August 2022	1 January 2023	Pharmacy Health (API Consumer Brands)
Bortezomib <sup>3</sup>	Inj 3.5 mg; 1 vial pack	\$105.00	\$74.93	DBL Bortezomib (Pfizer)	5%	1 December 2022	1 May 2023	Bortezomib Dr Reddy's (Dr Reddy's)



Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Listing date	Principal Supply Status date	Brand (Supplier) affected by delisting
Levomepromazine hydrochloride	Inj 25 mg per ml, 1 ml ampoule; 10 ampoule pack	\$33.50	\$24.48	Wockhardt (Max Health)	5%	1 November 2022	1 April 2023	Nozinan (Sanofi)
Liquid paraffin with white soft paraffin	Oint liquid paraffin 50% with white soft paraffin 50%; 100 g tube	\$1.97	\$1.84	White Soft Liquid Paraffin AFT (AFT)	5%	1 December 2022	1 May 2023	healthE (Jaychem)
Paracetamol <sup>4</sup>	Oral liq 120 mg per 5 ml; 200 ml bottle	\$5.45 (per 1,000 ml)	\$3.98	Paracetamol (Ethics) (Multichem NZ)	20%	1 January 2023	1 June 2023	Paracare (API Consumer Brands)
Paracetamol <sup>5</sup>	Oral liq 250 mg per 5 ml; 200 ml bottle	\$6.25 (per 1,000 ml)	\$3.35	Pamol (Aspen Pharma)	20%	1 November 2022	1 April 2023	Paracare Double Strength (API Consumer Brands)
Sodium cromoglicate	Eye drops 2%; 10 ml dropper bottle	\$1.79 (per 5 ml)	\$2.62	Allerfix (Teva)	5%	1 October 2022	1 March 2023	Rexacrom (Rex Medical)
Thiamine hydrochloride	Tab 50 mg; 100 tablet bottle	\$7.09	\$4.65	Thiamine multichem (Multichem)	5%	1 November 2022	1 April 2023	Max Health (Max Health)

<sup>2</sup> Stock is expected to become available within August, a 1 August 2022 Pharmaceutical Schedule listing date has been applied to enable dispensing of this product within August.

<sup>3</sup>The price and subsidy of bortezomib (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 December 2022. The subsidy of bortezomib inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will be amended from \$31.20 per 1 mg to \$22.26 per 1 mg from 1 December 2022. Bortezomib Dr Reddy's inj 3.5 mg vial will be delisted from 1 May 2023.

<sup>4</sup>The following presentations will also be delisted from 1 June 2023: "Paracetamol oral liq 120 mg per 5 ml – 100 ml bottle and "Paracetamol oral liq 120 mg per 5 ml – 500 ml bottle"

<sup>5</sup>The following presentations will also be delisted from 1 April 2023: "Paracetamol oral liq 250 mg per 5 ml – 100 ml bottle and "Paracetamol oral liq 250 mg per 5 ml – 500 ml bottle"

## Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021.

Chemical name	Line item
Adenosine	Inj 3 mg per ml, 2 ml vial
Levodopa with benserazide	Cap 100 mg with benserazide 25 mg
Levodopa with benserazide	Cap 200 mg with benserazide 50 mg
Levodopa with benserazide	Cap 50 mg with benserazide 12.5 mg
Levodopa with benserazide	Cap long-acting 100 mg with benserazide 25 mg
Levodopa with benserazide	Tab dispersible 50 mg with benserazide 12.5 mg
Levomepromazine	Tab 100 mg

Chemical name	Line item
Levomepromazine	Tab 25 mg
Levomepromazine	Tab 5 mg – 10 mg
Temozolomide	Cap 100 mg
Temozolomide	Cap 140 mg
Temozolomide	Cap 20 mg
Temozolomide	Cap 250 mg
Temozolomide	Cap 5 mg

For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.